1/21/2013

Drugmakers should open their information to the public, including trial data from drugs that have been reviewed and made available for clinical use, said a report issued by the Health Committee at the U.K.’s National Institute for Health and Clinical Excellence. “The committee believes there should be both a professional and legal obligation to ensure that all regulators, including NICE, have access to all the available research data about the efficacy and safety of pharmaceutical products,” the report said.

Full Story:
Pharmalot

Related Summaries